---
category: news
title: "The CEO of a $1.6 billion biotech says his bet on AI is paying off with faster, cheaper research that could reshape the industry"
excerpt: "Recursion says it can get drugs to the start of human testing at only 20% of the average cost while vetting potential treatments twice as fast."
publishedDateTime: 2023-01-25T14:30:00Z
originalUrl: "https://www.businessinsider.com/recursion-pharmaceuticals-ceo-interview-ai-in-biotech-2023-outlook-2023-1"
webUrl: "https://www.businessinsider.com/recursion-pharmaceuticals-ceo-interview-ai-in-biotech-2023-outlook-2023-1"
type: article
quality: 38
heat: 38
published: false

provider:
  name: Business Insider
  domain: businessinsider.com
  images:
    - url: "https://everyday-cc.github.io/ai/assets/images/organizations/businessinsider.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - AI

images:
  - url: "https://i.insider.com/63d05e2940fbb600192b50cc?width=1200&format=jpeg"
    width: 1200
    height: 600
    isCached: true

secured: "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;OgNXAjZ65W3fIcchWFsYzQ=="
---

